Serum prolactin level in patients with multiple sclerosis: A case control study

Mohammad H. Harirchian, Mohammad A. Sahraian, Afsaneh Shirani

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system and is considered to be multifactorial with an autoimmune component. Prolactin (PRL) is a neuroendocrine peptide with potent immunomodulatory properties. Hyperprolactinemia enhances several autoimmune disorders and may play a role in the pathogenesis of MS. The aim of this study was to compare serum PRL levels in MS patients with those of healthy controls. Material/Methods: There were 43 patients with definite MS and 43 sex- and age-matched healthy controls. Conditions leading to a rise in PRL, such as pregnancy, lactation, and specific underlying diseases and drugs, were excluded. PRL levels were measured in fasting blood samples. For the MS group, disease duration and subtype, clinical manifestations, and expanded disability status scores (EDSS) were also recorded. Results: There were no significant differences in serum PRL levels between the case and control groups in both women and men (376.78±231.11 mIU/l in female patients with MS vs. 364.19±202.55 mIU/l in female controls, 266.00±200.83 mIU/l in male patients with MS vs. 197.25±65.25 mIU/l in male controls). We also found no significant relationship between PRL and disease activity, disease duration, and EDSS. Conclusions: Our findings do not support the hypothesis that MS patients are in a hyperprolactinemic state. However, further studies in more homogenous MS subgroups are needed.

Original languageEnglish (US)
Pages (from-to)CR177-CR180
JournalMedical Science Monitor
Volume12
Issue number4
StatePublished - Apr 1 2006

Fingerprint

Prolactin
Multiple Sclerosis
Case-Control Studies
Serum
Hyperprolactinemia
Demyelinating Diseases
Lactation
Fasting
Central Nervous System
Pregnancy
Control Groups
Peptides
Pharmaceutical Preparations

Keywords

  • Hyperprolactinemia
  • Immunoendocrine
  • Multiple sclerosis
  • Prolactin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Serum prolactin level in patients with multiple sclerosis : A case control study. / Harirchian, Mohammad H.; Sahraian, Mohammad A.; Shirani, Afsaneh.

In: Medical Science Monitor, Vol. 12, No. 4, 01.04.2006, p. CR177-CR180.

Research output: Contribution to journalArticle

Harirchian, Mohammad H. ; Sahraian, Mohammad A. ; Shirani, Afsaneh. / Serum prolactin level in patients with multiple sclerosis : A case control study. In: Medical Science Monitor. 2006 ; Vol. 12, No. 4. pp. CR177-CR180.
@article{1fcc6d6cbdf9498fb6f2b74cd761e347,
title = "Serum prolactin level in patients with multiple sclerosis: A case control study",
abstract = "Background: Multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system and is considered to be multifactorial with an autoimmune component. Prolactin (PRL) is a neuroendocrine peptide with potent immunomodulatory properties. Hyperprolactinemia enhances several autoimmune disorders and may play a role in the pathogenesis of MS. The aim of this study was to compare serum PRL levels in MS patients with those of healthy controls. Material/Methods: There were 43 patients with definite MS and 43 sex- and age-matched healthy controls. Conditions leading to a rise in PRL, such as pregnancy, lactation, and specific underlying diseases and drugs, were excluded. PRL levels were measured in fasting blood samples. For the MS group, disease duration and subtype, clinical manifestations, and expanded disability status scores (EDSS) were also recorded. Results: There were no significant differences in serum PRL levels between the case and control groups in both women and men (376.78±231.11 mIU/l in female patients with MS vs. 364.19±202.55 mIU/l in female controls, 266.00±200.83 mIU/l in male patients with MS vs. 197.25±65.25 mIU/l in male controls). We also found no significant relationship between PRL and disease activity, disease duration, and EDSS. Conclusions: Our findings do not support the hypothesis that MS patients are in a hyperprolactinemic state. However, further studies in more homogenous MS subgroups are needed.",
keywords = "Hyperprolactinemia, Immunoendocrine, Multiple sclerosis, Prolactin",
author = "Harirchian, {Mohammad H.} and Sahraian, {Mohammad A.} and Afsaneh Shirani",
year = "2006",
month = "4",
day = "1",
language = "English (US)",
volume = "12",
pages = "CR177--CR180",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "4",

}

TY - JOUR

T1 - Serum prolactin level in patients with multiple sclerosis

T2 - A case control study

AU - Harirchian, Mohammad H.

AU - Sahraian, Mohammad A.

AU - Shirani, Afsaneh

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Background: Multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system and is considered to be multifactorial with an autoimmune component. Prolactin (PRL) is a neuroendocrine peptide with potent immunomodulatory properties. Hyperprolactinemia enhances several autoimmune disorders and may play a role in the pathogenesis of MS. The aim of this study was to compare serum PRL levels in MS patients with those of healthy controls. Material/Methods: There were 43 patients with definite MS and 43 sex- and age-matched healthy controls. Conditions leading to a rise in PRL, such as pregnancy, lactation, and specific underlying diseases and drugs, were excluded. PRL levels were measured in fasting blood samples. For the MS group, disease duration and subtype, clinical manifestations, and expanded disability status scores (EDSS) were also recorded. Results: There were no significant differences in serum PRL levels between the case and control groups in both women and men (376.78±231.11 mIU/l in female patients with MS vs. 364.19±202.55 mIU/l in female controls, 266.00±200.83 mIU/l in male patients with MS vs. 197.25±65.25 mIU/l in male controls). We also found no significant relationship between PRL and disease activity, disease duration, and EDSS. Conclusions: Our findings do not support the hypothesis that MS patients are in a hyperprolactinemic state. However, further studies in more homogenous MS subgroups are needed.

AB - Background: Multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system and is considered to be multifactorial with an autoimmune component. Prolactin (PRL) is a neuroendocrine peptide with potent immunomodulatory properties. Hyperprolactinemia enhances several autoimmune disorders and may play a role in the pathogenesis of MS. The aim of this study was to compare serum PRL levels in MS patients with those of healthy controls. Material/Methods: There were 43 patients with definite MS and 43 sex- and age-matched healthy controls. Conditions leading to a rise in PRL, such as pregnancy, lactation, and specific underlying diseases and drugs, were excluded. PRL levels were measured in fasting blood samples. For the MS group, disease duration and subtype, clinical manifestations, and expanded disability status scores (EDSS) were also recorded. Results: There were no significant differences in serum PRL levels between the case and control groups in both women and men (376.78±231.11 mIU/l in female patients with MS vs. 364.19±202.55 mIU/l in female controls, 266.00±200.83 mIU/l in male patients with MS vs. 197.25±65.25 mIU/l in male controls). We also found no significant relationship between PRL and disease activity, disease duration, and EDSS. Conclusions: Our findings do not support the hypothesis that MS patients are in a hyperprolactinemic state. However, further studies in more homogenous MS subgroups are needed.

KW - Hyperprolactinemia

KW - Immunoendocrine

KW - Multiple sclerosis

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=33645536260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645536260&partnerID=8YFLogxK

M3 - Article

C2 - 16572053

AN - SCOPUS:33645536260

VL - 12

SP - CR177-CR180

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 4

ER -